PT814788E - Aumento da tolerancia a glucose - Google Patents

Aumento da tolerancia a glucose Download PDF

Info

Publication number
PT814788E
PT814788E PT95909382T PT95909382T PT814788E PT 814788 E PT814788 E PT 814788E PT 95909382 T PT95909382 T PT 95909382T PT 95909382 T PT95909382 T PT 95909382T PT 814788 E PT814788 E PT 814788E
Authority
PT
Portugal
Prior art keywords
glucose tolerance
compound
humans
insulin dependent
enantiomers
Prior art date
Application number
PT95909382T
Other languages
English (en)
Portuguese (pt)
Inventor
Ramon Vargas
Original Assignee
Knoll Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22703362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT814788(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Knoll Pharmaceutical Co filed Critical Knoll Pharmaceutical Co
Publication of PT814788E publication Critical patent/PT814788E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Lubricants (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
PT95909382T 1994-02-03 1995-02-03 Aumento da tolerancia a glucose PT814788E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/190,924 US5459164A (en) 1994-02-03 1994-02-03 Medical treatment

Publications (1)

Publication Number Publication Date
PT814788E true PT814788E (pt) 2002-03-28

Family

ID=22703362

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95909382T PT814788E (pt) 1994-02-03 1995-02-03 Aumento da tolerancia a glucose

Country Status (17)

Country Link
US (2) US5459164A (cg-RX-API-DMAC10.html)
EP (1) EP0814788B1 (cg-RX-API-DMAC10.html)
JP (1) JPH10503166A (cg-RX-API-DMAC10.html)
KR (1) KR100339874B1 (cg-RX-API-DMAC10.html)
CN (1) CN1070698C (cg-RX-API-DMAC10.html)
AT (1) ATE205390T1 (cg-RX-API-DMAC10.html)
AU (1) AU694761B2 (cg-RX-API-DMAC10.html)
CA (1) CA2182620C (cg-RX-API-DMAC10.html)
DE (1) DE69522716T2 (cg-RX-API-DMAC10.html)
DK (1) DK0814788T3 (cg-RX-API-DMAC10.html)
ES (1) ES2166817T3 (cg-RX-API-DMAC10.html)
IL (1) IL112515A (cg-RX-API-DMAC10.html)
PH (1) PH31220A (cg-RX-API-DMAC10.html)
PT (1) PT814788E (cg-RX-API-DMAC10.html)
TW (1) TW314466B (cg-RX-API-DMAC10.html)
WO (1) WO1995020949A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA95814B (cg-RX-API-DMAC10.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
CA2366660A1 (en) * 1999-03-19 2000-09-28 Carl M. Mendel Treatment of osteoarthritis
AU3896900A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of pain
US6441046B1 (en) 1999-03-19 2002-08-27 Abbott Gmbh & Co. Kg Control of metabolism
US6433020B1 (en) * 1999-03-19 2002-08-13 Knoll Pharmaceutical Company Treatment of cardiovascular disease
US6376554B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Method of treating sexual dysfunction
TR200102695T2 (tr) * 1999-03-19 2002-01-21 Knoll Gmbh Tedavi edici ilaçlarla ilişkili olarak kilo alımının kontrol edilmesi
PL351958A1 (en) * 1999-03-19 2003-07-14 Knoll Gmbh Treatment of some tumours associated with gain in weight
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
CA2368416A1 (en) * 1999-03-19 2000-09-28 Knoll Gmbh Treatment of gallstones
AU3895300A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
US6372797B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of menstrual function
WO2000056319A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
HUP0200501A3 (en) * 1999-03-19 2004-03-29 Abbott Gmbh & Co Kg Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treating sleep apnoea
WO2000056312A1 (en) * 1999-03-19 2000-09-28 Knoll Gmbh Treatment of pulmonary hypertension
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9926251D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Pharmaceutical formulation
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
WO2002083631A1 (en) * 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
MXPA05003355A (es) * 2002-10-05 2005-10-18 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende semihidrato de metansulfonato de sibutramina cristalino.
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
WO2006073292A1 (en) 2005-01-06 2006-07-13 Cj Corporation Inorganic acid salts of sibutramine
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
BRPI0716002A2 (pt) * 2006-11-22 2013-07-30 Sk Chemicals Co Ltd complexo de inclusço, processo de preparaÇço de um complexo de inclusço e composiÇço de tratamento e prevenÇço de hipocondria e obesidade

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
ATE93721T1 (de) * 1987-05-04 1993-09-15 Lilly Co Eli Verwendung von fluoxetin zur behandlung des diabetes.
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
KR100339874B1 (ko) 2002-11-22
EP0814788B1 (en) 2001-09-12
US5459164A (en) 1995-10-17
CA2182620C (en) 2007-01-16
DE69522716T2 (de) 2002-05-29
EP0814788A4 (en) 1999-05-06
US5942549A (en) 1999-08-24
TW314466B (cg-RX-API-DMAC10.html) 1997-09-01
EP0814788A1 (en) 1998-01-07
WO1995020949A1 (en) 1995-08-10
IL112515A (en) 2000-07-26
DE69522716D1 (de) 2001-10-18
ATE205390T1 (de) 2001-09-15
AU1736295A (en) 1995-08-21
CA2182620A1 (en) 1995-08-10
PH31220A (en) 1998-05-05
AU694761B2 (en) 1998-07-30
ES2166817T3 (es) 2002-05-01
IL112515A0 (en) 1995-12-08
CN1070698C (zh) 2001-09-12
JPH10503166A (ja) 1998-03-24
ZA95814B (en) 1995-08-03
CN1144479A (zh) 1997-03-05
DK0814788T3 (da) 2001-11-19

Similar Documents

Publication Publication Date Title
EP0814788B1 (en) Improving glucose tolerance
ES2199374T3 (es) Derivados de 1-(1-(4-clorofenil)ciclobutil)-3-metilbutilamina para reducir el nivel de acido urico en seres humanos.
US6376553B1 (en) Treatment of pain
ES2244420T3 (es) Utilizacion de la sibutramina o de uno de sus derivados para el tratamiento de los trastornos del sueño.
AU3757800A (en) Method of controlling weight gain associated with therapeutic drugs
WO2000056318A1 (en) Treatment of neuropathic pain or fibromyalgia
US6372797B1 (en) Treatment of menstrual function
US6441046B1 (en) Control of metabolism
US6380260B1 (en) Treatment to lower platelet adhesiveness
AU773490B2 (en) Treatment of osteoarthritis
US6803387B1 (en) Treatment of neuropathic pain or fibromyalgia
US6365632B1 (en) Treatment of orthostatic hypotension
US6403650B1 (en) Treatment of pulmonary hypertension
WO2000056150A1 (en) Treatment of premenstrual syndrome
US20030008897A1 (en) Method of controlling weight gain associated with therapeutic drugs
US20030013735A1 (en) Weight loss after pregnancy
AU3894400A (en) Treatment of hiatial hernia
AU3632000A (en) Treatment of certain cancers associated with weight gain
AU4172900A (en) Weight loss after pregnancy